Meeting
2020 Genitourinary Cancers Symposium
A phase I study to evaluate PSCA-targeting chimeric antigen receptor (CAR)-T cells for patients with PSCA+ metastatic castration-resistant prostate cancer (mCRPC).
Authors
Tanya B. Dorff
City of Hope, Duarte, CA
Tanya B. Dorff , Suzette Blanchard , Patti Carruth , Jamie Wagner , Peter Kuhn , Ammar Chaudhry , Lauren Adkins , Sandra Thomas , Hripsime Martirosyan , Peiguo Chu , Sumanta K. Pal , Stephen J. Forman , Saul Priceman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03873805
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS250)
Abstract #
TPS250
Poster Bd #
N16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC).
First Author: Tanya B. Dorff
Poster
2022 ASCO Annual Meeting
A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel Costin Danila
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1 study of PSCA-targeted chimeric antigen receptor (CAR) T cell therapy for metastatic castration-resistant prostate cancer (mCRPC).
First Author: Tanya B. Dorff
Poster
2021 Genitourinary Cancers Symposium
Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: William Kevin Kelly